Evotec AG Fiscal Year Results 2016: Leading Innovation Efficiency & First-in-Class Drug Discovery
HAMBURG, Germany--(BUSINESS WIRE)--Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced its financial results and corporate updates for the fiscal year ended 31 December 2016.
FINANCIAL PERFORMANCE - ALL FINANCIAL TARGETS ACHIEVED
- Total Group revenues up 29% to EUR 164.5 m (2015: EUR 127.7 m); base revenues up 26% to EUR 145.6 m
- Strong revenue growth in both operating segments: EVT Execute revenues up 28% to EUR 171.0 m (2015: EUR 134.0 m); EVT Innovate revenues up 24% to EUR 26.7 m (2015: EUR 21.5 m)
- Adjusted Group EBITDA increased to EUR 36.2 m (2015: EUR 8.7 m)
- Stable Group R&D expenses of EUR 18.1 m (2015: EUR 18.3 m)
- High and solid liquidity position of EUR 126.3 m (2015: EUR 133.9 m) by the end of 2016; Liquidity position further improved in Q1 2017 following EUR 90.3 m capital increase with Novo A/S
FINANCIAL PERFORMANCE - ALL FINANCIAL TARGETS ACHIEVED
- Total Group revenues up 29% to EUR 164.5 m (2015: EUR 127.7 m); base revenues up 26% to EUR 145.6 m
- Strong revenue growth in both operating segments: EVT Execute revenues up 28% to EUR 171.0 m (2015: EUR 134.0 m); EVT Innovate revenues up 24% to EUR 26.7 m (2015: EUR 21.5 m)
- Adjusted Group EBITDA increased to EUR 36.2 m (2015: EUR 8.7 m)
- Stable Group R&D expenses of EUR 18.1 m (2015: EUR 18.3 m)
- High and solid liquidity position of EUR 126.3 m (2015: EUR 133.9 m) by the end of 2016; Liquidity position further improved in Q1 2017 following EUR 90.3 m capital increase with Novo A/S